Cost-effectiveness of a real-time spatiotemporal mapping surveillance system for meticillin-resistant Staphylococcus aureus prevention
Copyright © 2023. Published by Elsevier Ltd..
OBJECTIVES: An infection surveillance system based on a hospital's digital twin [4D-Disease Outbreak Surveillance System (4D-DOSS)] is being developed in Singapore. It offers near-real-time infection surveillance and mapping capabilities. This early economic modelling study was conducted, using meticillin-resistant Staphylococcus aureus (MRSA) as the pathogen of interest, to assess the potential cost-effectiveness of 4D-DOSS.
METHODS: A Markov model that simulates the likelihood of MRSA colonization and infection was developed to evaluate the cost-effectiveness of adopting 4D-DOSS for MRSA surveillance from the hospital perspective, compared with current practice. The cycle duration was 1 day, and the model horizon was 30 days. Probabilistic sensitivity analysis was conducted, and the probability of cost-effectiveness was reported. Scenario analyses and a value of information analysis were performed.
RESULTS: In the base-case scenario, with 10-year implementation/maintenance costs of 4D-DOSS of $0, there was 68.6% chance that 4D-DOSS would be cost-effective. In a more pessimistic but plausible scenario where the effectiveness of 4D-DOSS in reducing MRSA transmission was one-quarter of the base-case scenario with 10-year implementation/maintenance costs of $1 million, there was 47.7% chance that adoption of 4D-DOSS would be cost-effective. The value of information analysis showed that uncertainty in MRSA costs made the greatest contribution to model uncertainty.
CONCLUSIONS: This early-stage modelling study revealed the circumstances for which 4D-DOSS is likely to be cost-effective at the current willingness-to-pay threshold, and identified the parameters for which further research will be worthwhile to reduce model uncertainty. Inclusion of other drug-resistant organisms will provide a more thorough assessment of the cost-effectiveness of 4D-DOSS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
The Journal of hospital infection - 143(2024) vom: 30. Jan., Seite 178-185 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cai, Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Health technology assessment |
|---|
| Anmerkungen: |
Date Completed 16.01.2024 Date Revised 31.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jhin.2023.09.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362710309 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362710309 | ||
| 003 | DE-627 | ||
| 005 | 20240131231916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhin.2023.09.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM362710309 | ||
| 035 | |a (NLM)37774929 | ||
| 035 | |a (PII)S0195-6701(23)00309-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cai, Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness of a real-time spatiotemporal mapping surveillance system for meticillin-resistant Staphylococcus aureus prevention |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2024 | ||
| 500 | |a Date Revised 31.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVES: An infection surveillance system based on a hospital's digital twin [4D-Disease Outbreak Surveillance System (4D-DOSS)] is being developed in Singapore. It offers near-real-time infection surveillance and mapping capabilities. This early economic modelling study was conducted, using meticillin-resistant Staphylococcus aureus (MRSA) as the pathogen of interest, to assess the potential cost-effectiveness of 4D-DOSS | ||
| 520 | |a METHODS: A Markov model that simulates the likelihood of MRSA colonization and infection was developed to evaluate the cost-effectiveness of adopting 4D-DOSS for MRSA surveillance from the hospital perspective, compared with current practice. The cycle duration was 1 day, and the model horizon was 30 days. Probabilistic sensitivity analysis was conducted, and the probability of cost-effectiveness was reported. Scenario analyses and a value of information analysis were performed | ||
| 520 | |a RESULTS: In the base-case scenario, with 10-year implementation/maintenance costs of 4D-DOSS of $0, there was 68.6% chance that 4D-DOSS would be cost-effective. In a more pessimistic but plausible scenario where the effectiveness of 4D-DOSS in reducing MRSA transmission was one-quarter of the base-case scenario with 10-year implementation/maintenance costs of $1 million, there was 47.7% chance that adoption of 4D-DOSS would be cost-effective. The value of information analysis showed that uncertainty in MRSA costs made the greatest contribution to model uncertainty | ||
| 520 | |a CONCLUSIONS: This early-stage modelling study revealed the circumstances for which 4D-DOSS is likely to be cost-effective at the current willingness-to-pay threshold, and identified the parameters for which further research will be worthwhile to reduce model uncertainty. Inclusion of other drug-resistant organisms will provide a more thorough assessment of the cost-effectiveness of 4D-DOSS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Health technology assessment | |
| 650 | 4 | |a Infection prevention and control | |
| 650 | 4 | |a Outbreak response | |
| 650 | 7 | |a Methicillin |2 NLM | |
| 650 | 7 | |a Q91FH1328A |2 NLM | |
| 700 | 1 | |a Philips, E C |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, S |e verfasserin |4 aut | |
| 700 | 1 | |a Sim, J X Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, W |e verfasserin |4 aut | |
| 700 | 1 | |a Nazeha, N |e verfasserin |4 aut | |
| 700 | 1 | |a Whiteley, S |e verfasserin |4 aut | |
| 700 | 1 | |a Auw, M Y X |e verfasserin |4 aut | |
| 700 | 1 | |a Tiang, D C |e verfasserin |4 aut | |
| 700 | 1 | |a Neo, S L |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, W |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatachalam, I |e verfasserin |4 aut | |
| 700 | 1 | |a Graves, N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of hospital infection |d 1993 |g 143(2024) vom: 30. Jan., Seite 178-185 |w (DE-627)NLM012638692 |x 1532-2939 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2024 |g day:30 |g month:01 |g pages:178-185 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhin.2023.09.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2024 |b 30 |c 01 |h 178-185 | ||